REG - e-Therapeutics plc - Update on OTCQX Market Listing

E-TherapeuticsAnnouncement

27/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231227:nRSa8471Xa&default-theme=true

RNS Number : 8471X  e-Therapeutics plc  27 December 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Update on OTCQX Market Listing

 

 

London, UK, 27 December 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF),
a company integrating computational power and biological data to discover
life-transforming RNAi medicines, today announces that, with effect from 31
December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on
the OTCQX Best Market in the United States ("OTCQX").

The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but
there has been limited trading since that date. As such, the expenses
associated with the Company's Ordinary Shares trading on OTCQX outweigh the
benefits for e-therapeutics shareholders.

The Ordinary Shares will continue to be admitted to trading on AIM as the
Company's primary market.

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                    Tel: +44 (0)20 4551 8888

 Timothy Bretherton,                                                                   www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)
 CFO

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.

 

ETX's proprietary HepNet™ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises, and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet™. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic™
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class RNAi candidates across
a variety of therapeutic areas with high unmet need, including preclinical
programs in cardiometabolic and metabolic diseases, haemophilia, and other
undisclosed indications. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPGGGPUPWPUQ